Delving into the Latest Updates on Hydrocortisone with Synapse

Overview

Basic Info

SummaryHydrocortisone, a diminutive yet powerful molecule, is renowned for its aptitude to function as a glucocorticoid receptor (GR) agonist, thereby stimulating the GR. This drug boasts a diverse range of clinical applications and is typically employed in the treatment of a multitude of ailments that are closely associated with adrenal insufficiency, including but not limited to congenital adrenal hyperplasia, adrenal hyperplasia, Addison's disease, and isolated ACTH deficiency. Additionally, it has proven efficacious in treating inflammatory conditions such as subacute thyroiditis, ulcerative colitis, proctocolitis, and ulcerative proctitis. It is worth noting that the FDA initially granted its approval to hydrocortisone on the 5th of August, 1952. The development of hydrocortisone is credited to Merck Sharp & Dohme Corp, which pioneered the drug. Owing to its extraordinary anti-inflammatory and immunosuppressive qualities, hydrocortisone has emerged as a definitive remedy for numerous chronic inflammatory disorders.

Drug Type

Small molecule drug

Synonyms

(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione, 11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione, 11beta-hydrocortisone

+ [59]

Target

GR

Mechanism

GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [10]

Active Indication

Adrenal Hyperplasia, CongenitalACTH Deficiency, IsolatedAdrenal Insufficiency+ [20]

Inactive Indication

Adult Lymphoblastic LymphomaNon-Hodgkin LymphomaRecurrent Adult Acute Lymphoblastic Leukemia+ [2]

Originator Organization

Merck Sharp & Dohme Corp.

Active Organization

ANI Pharmaceuticals, Inc.

Neurocrine Biosciences, Inc.Pharmacia & Upjohn, Inc.

+ [5]

Inactive Organization

Takeda Pharmaceutical Co., Ltd.

Merck & Co., Inc.

Shire Plc

Drug Highest PhaseApproved

First Approval Date

US (05 Aug 1952),

Endocrine System DiseasesHypersensitivityImmune System Diseases+ [1]

RegulationFast Track (US), Orphan Drug (US), Orphan Drug (AU), Orphan Drug (EU)

Login to view timeline

Structure/Sequence

Molecular FormulaC21H30O5

InChIKeyJYGXADMDTFJGBT-VWUMJDOOSA-N

CAS Registry50-23-7

PALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments. Treatable traits, therapeutic targets identified by phenotypes or endotypes (defined by biological mechanism or by treatment response) through validated biomarkers (measurable characteristic reflecting normal or pathogenic processes, or treatment responses), may include multi-omics, cellular, immune, metabolic, endocrine features, or intelligent algorithms. PALETTE Bayesian adaptive design enables parallel investigations of multiple interventions for sepsis, and quick inclusion of pandemic pathogens. PALETTE's new conceptual model will respond to the challenges of standard approaches, i.e. series of sepsis trials, each investigating one or two interventions, expensive, time consuming, and inappropriate in pandemic context.

Start Date01 Apr 2026

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

NCT04231708

/ Not yet recruitingPhase 2IIT

Effects of Pharmacological Stress and Repetitive Transcranial Magnetic Stimulation Interventions on Executive Function in Opioid Use Disorder

This preliminary study is designed to evaluate mechanisms by which excitatory dorsolateral prefrontal cortex (dlPFC) repetitive transcranial magnetic stimulation (rTMS) (vs. sham) and pharmacological stress (vs. placebo) alter behavior in non-treatment seeking individuals with opioid use disorder (OUD). Specific Aims are to (1) Evaluate how stress impacts domains of behavior including (1a) executive function and (1b) opioid-seeking behavior; and (2) Determine whether rTMS stimulation attenuates (2a) executive dysfunction, (2b) stress-reactivity, and (2c) opioid-seeking in individuals with OUD not receiving treatment.

Start Date01 Jun 2025

Sponsor / Collaborator

Wayne State University (Michigan)

NCT06317662

/ Not yet recruitingPhase 2IIT

A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged [R]) or without a KMT2A gene rearrangement (KMT2A-germline [G]). Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding venetoclax and/or blinatumomab to standard chemotherapy may be more effective at treating patients with ALL than standard chemotherapy alone, but it may also cause more side effects. This clinical trial evaluates the safety and effectiveness of adding venetoclax and/or blinatumomab to chemotherapy for the treatment of infants with KMT2A-R or KMT2A-G ALL.

Start Date26 Apr 2025

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Hydrocortisone

Login to view more data

100 Translational Medicine associated with Hydrocortisone

Login to view more data

100 Patents (Medical) associated with Hydrocortisone

Login to view more data

90,662

Literatures (Medical) associated with Hydrocortisone

31 Dec 2025·STRESS-THE INTERNATIONAL JOURNAL ON THE BIOLOGY OF STRESS

Differences in hair cortisol to cortisone ratio between depressed and non-depressed adolescent women

Article

Author: Garel, Patricia ; Herba, Catherine M. ; Porter-Vignola, Elyse ; Marin, Marie-France ; Zerroug, Yasmine

Research on stress has demonstrated that the hypothalamic-pituitary-adrenal (HPA) axis contributes to major depressive disorder in youth. Hair glucocorticoids are key biological markers of chronic stress. We assessed group differences in hair cortisol and cortisone concentrations, and the cortisol/cortisone ratio between depressed adolescent women and a non-depressed comparison group. Further, within the depression group, we explored the contribution of symptom severity and clinical correlates of depression in relation to glucocorticoid concentrations. Hair samples of three centimeters for 74 adolescent women (41 in the depression group and 33 in the comparison group), aged between 12 and 19 years old, were analyzed. Depressive and anxiety symptoms were measured using the Beck Youth Inventory II and clinical correlates of depression were measured using the Childhood Trauma Questionnaire-Short Form and the Borderline Personality Features Scale for Children. No significant differences emerged between the depression group and the comparison group on hair cortisol or hair cortisone concentrations. However, groups differed significantly on the cortisol/cortisone ratio, a proposed proxy of 11-beta-hydroxysteroid dehydrogenase activity, with a higher ratio for the depression group. Within the depression group, neither symptom severity nor clinical correlates were associated with glucocorticoid concentrations. Although cross-sectional, our findings highlight the importance of future studies to test whether the group difference found in cortisol/cortisone ratio is the result of alterations in 11-beta-hydroxysteroid dehydrogenase enzymes (type 1 or 2) activity. Further research is thus needed to clarify the role of these enzymes in major depressive disorder in youth and to develop more targeted intervention strategies.

31 Dec 2025·ANNALS OF MEDICINE

High-dose glucocorticoid treatment vs. glucocorticoid replacement in immune checkpoint inhibitor associated hypophysitis (CORTICI): an open, randomised controlled trial

Article

Author: Theiler-Schwetz, Verena ; Obermayer-Pietsch, Barbara ; Pilz, Stefan ; Schmitt, Lisa ; Trummer, Christian ; Richtig, Erika ; Terbuch, Angelika

OBJECTIVE:

One of the most severe endocrine side effects of immune checkpoint inhibitors (ICI) is hypophysitis leading to adrenal insufficiency. Recovery is rare, although it has been reported after high-dose glucocorticoid treatment. This is the first randomised study to evaluate whether hormonal recovery differs in patients treated with high-dose glucocorticoids versus glucocorticoid replacement therapy.

DESIGN/METHODS:

In this single-centre, open, randomised controlled study, patients with ICI associated hypophysitis were randomised 1:1 to high-dose glucocorticoid treatment (1 mg/kg of prednisolone for two weeks, followed by tapering until week 7 and a switch to hydrocortisone 20 mg total daily dose in week 8) or glucocorticoid replacement therapy (hydrocortisone 20 mg total daily dose) over 8 weeks. The primary outcome was the frequency of hormonal axes recovery.

RESULTS:

Between 17th April 2019 and 16th September 2022, 18 out of the 20 randomised patients finished the trial; eight completed high-dose, 10 glucocorticoid replacement. Nine patients presented with hyponatraemia, two had typical changes on MRI, 12 had isolated adrenal insufficiency, and six had an additional hormone deficiency. None of the patients in neither group experienced a recovery in adrenal function. One patient in each group showed amelioration of hypogonadism. There was a significant, unfavourable treatment effect of high-dose treatment on HbA1c (mean treatment effect 5.16, 95% confidence interval 0.31 to 10.02, p = 0.039).

CONCLUSIONS:

High-dose glucocorticoid treatment was not effective in restoring adrenal function and leads to adverse effects on glucose metabolism. We therefore do not recommend its use for the treatment of ICI associated hypophysitis, except for compressive symptoms.

01 Jun 2025·BIOELECTROCHEMISTRY

Conductive and flexible gold-coated polylactic acid nanofiber-based electrochemical aptasensor for monitoring cortisol level in sweat and saliva

Article

Author: Koumbia, Mkliwa ; Madoka, Takai

Conductive nanofibers can exhibit excellent mechanical properties such as flexibility, elasticity, porosity, large surface area-to-volume ratio, etc making them suitable for a wide range of applications including biosensor development. Their large surface area provides more active sites for immobilization of large amount of bioreceptors enabling more interaction sites with the target analytes, enhancing sensitivity and detection capabilities. However, engineering conductive nanofibers with such excellent properties is challenging limiting their effective deployment for intended applications. In this research, we propose a novel approach for easy fabrication of highly conductive and flexible nanofiber leveraging the electrospinning, electroless deposition and have applied it to cortisol monitoring; a common biomarker for stress which is often quantified through enzyme-linked immunoassays using blood or saliva samples. By adopting the nanofiber sheet as a transducer for aptamer immobilization and cortisol sensing our developed biosensor was able to detect cortisol in buffer, artificial saliva, and artificial sweat within five minutes, from 10 pg/mL to 10 µg/mL (27.59 pM to 27.59 µM) with a low detection limit of 1 pg/ml (2.76 pM). The Au-coated PLA nanofiber-based electrochemical biosensor's flexibility allows for compact manufacturing, rendering it an optimal choice for integration into point-of-care testing and wearable systems.

116

News (Medical) associated with Hydrocortisone

10 Feb 2025

·www.pharmaceutical-technology.com

Eton secures US patent for diabetes insipidus treatment

ET-600 is involved in a pivotal bioequivalence study. Credit: shisu_ka/Shutterstock. Eton Pharmaceuticals has secured a patent from the US Patent and Trademark Office (USPTO) for its ET-600 product candidate’s desmopressin oral solution formulation for diabetes insipidus, which affects around one in 25,000 children – almost 3,000 US paediatric subjects annually. It causes the body to produce an excessive amount of urine, leading to severe dehydration and potentially delayed or stunted growth if untreated. The US Patent No 12,214,010, which expires in 2044, is expected to be listed in the Orange Book of the Food and Drug Administration (FDA) following the product’s approval. An additional patent application related to ET-600 is under review. Eton Pharmaceuticals CEO Sean Brynjelsen stated: “This patent strengthens our growing intellectual property portfolio and underscores our commitment to delivering innovative treatments to underserved patient populations. “The paediatric endocrinology community has expressed the significant need for a liquid form of desmopressin that can accurately and efficiently deliver small doses for children, and we are proud to have developed a formulation to meet their needs and to see our innovation recognised with a patent.” Desmopressin is approved in tablet, nasal and injectable forms, but does not completely meet the paediatric need for precise, titratable [able to determine the smallest concentration required to bring about a given effect] and small doses. Consequently, paediatric subjects often rely on unapproved liquid suspensions from compounding pharmacies, cut and measure fractional tablets, or resort to daily injections ET-600 is presently in a pivotal bioequivalence study and passed a similar trial in 2024. Eton expects the outcomes of the study at the end of February 2025. It anticipates filing a new drug application with the US regulator by the second quarter of 2025 if outcomes are positive. Eton’s other product candidates in late-stage development are Zeneo hydrocortisone autoinjector, ET-400 and Amglidia. In November 2024, the company acquired the US rights to Amglidia, a treatment for neonatal diabetes mellitus, from French biotechnology company AMMTeK.

Drug ApprovalPatent Expiration

07 Feb 2025

·ir.etonpharma.com

Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600

« Back to news - Product has patent protection through 2044 - - Expected to be listed in the U.S. Food and Drug Administration’s (FDA) Orange Book upon the product’s approval – DEER PARK, Ill., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the United States Patent and Trademark Office (USPTO) has granted the Company U.S. Patent No. 12,214,010, covering its ET-600 product candidate’s proprietary formulation of desmopressin oral solution. The patent expires in 2044 and is expected to be listed in the FDA Orange Book upon the product’s approval. The Company has an additional patent application related to the product under review with the USPTO. ET-600 is a proprietary formulation of desmopressin oral solution under development for the treatment of diabetes insipidus. Desmopressin is the standard of care for diabetes insipidus, but there is not an FDA-approved oral liquid formulation. Currently, desmopressin is only FDA-approved in injectable, tablet, and nasal form, none of which fully meet the pediatric need for small, precise, and titratable doses. As a result, most pediatric patients use unapproved liquid suspensions from compounding pharmacies, attempt to cut and measure fractional tablets, or take daily injections. “This patent strengthens our growing intellectual property portfolio and underscores our commitment to delivering innovative treatments to underserved patient populations. The pediatric endocrinology community has expressed the significant need for a liquid form of desmopressin that can accurately and efficiently deliver small doses for children, and we are proud to have developed a formulation to meet their needs and to see our innovation recognized with a patent,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. ET-600 previously passed a pilot bioequivalence study in 2024 and is currently undergoing its pivotal bioequivalence study. The Company expects to have study results at the end of February. If results are positive, the company anticipates filing a New Drug Application (NDA) with the FDA for the product by the second quarter of 2025. About Diabetes Insipidus Diabetes insipidus is a rare condition in which the body produces too much urine and is not able to retain water. If left untreated, diabetes insipidus can cause excessive dehydration and delayed or stunted growth in children. The condition is estimated to affect about 1 in 25,000 people, or approximately 3,000 pediatric patients in the United States. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Relations: Lisa M. Wilson, In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com Source: Eton Pharmaceuticals, Inc. Source: Eton Pharmaceuticals

Drug ApprovalNDA

06 Feb 2025

·ir.etonpharma.com

Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400

DEER PARK, Ill., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the New Drug Application (NDA) for ET-400. The new PDUFA goal date is May 28, 2025. The Company was notified that the FDA requires additional time to conduct a full review of supplemental information that was provided in December in response to an FDA request. The FDA communicated that it has applied a standard three-month extension from the original goal date of February 28, 2025. Eton believes it has fully addressed all questions from the FDA and there are no outstanding requests. “We are confident in the strength of our NDA package and look forward to ensuring access to patients in need of this important pediatric rare disease therapy immediately after FDA approval this year. We do not expect this standard extension to significantly affect our internal 2025 revenue projections,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Relations: Lisa M. Wilson, In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com Source: Eton Pharmaceuticals, Inc. Source: Eton Pharmaceuticals

NDA

100 Deals associated with Hydrocortisone

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00088	Hydrocortisone	D07AA02 A01AC03 S02BA01	DB00741

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Adrenal Hyperplasia, Congenital	EU	Neurocrine Biosciences, Inc.	27 May 2021
Adrenal Hyperplasia, Congenital	IS	Neurocrine Biosciences, Inc.	27 May 2021
Adrenal Hyperplasia, Congenital	LI	Neurocrine Biosciences, Inc.	27 May 2021
Adrenal Hyperplasia, Congenital	NO	Neurocrine Biosciences, Inc.	27 May 2021
ACTH Deficiency, Isolated	JP	Pfizer Japan, Inc.	21 Dec 1972
Adrenal Insufficiency	JP	Pfizer Japan, Inc.	21 Dec 1972
Infectious Diseases	JP	Pfizer Japan, Inc.	21 Dec 1972
Thyroiditis, Subacute	JP	Pfizer Japan, Inc.	21 Dec 1972
Colitis, Ulcerative	US	ANI Pharmaceuticals, Inc.	12 Jan 1966
Proctocolitis	US	ANI Pharmaceuticals, Inc.	12 Jan 1966
Ulcerative proctitis	US	ANI Pharmaceuticals, Inc.	12 Jan 1966
Anaphylaxis	US	Pharmacia & Upjohn, Inc.	15 Dec 1952
Collagen Diseases	US	Pharmacia & Upjohn, Inc.	15 Dec 1952
Edema	US	Pharmacia & Upjohn, Inc.	15 Dec 1952
Eye Diseases	US	Pharmacia & Upjohn, Inc.	15 Dec 1952
Gastrointestinal Diseases	US	Pharmacia & Upjohn, Inc.	15 Dec 1952
Hematologic Diseases	US	Pharmacia & Upjohn, Inc.	15 Dec 1952
Neoplasms	US	Pharmacia & Upjohn, Inc.	15 Dec 1952
Respiratory Diseases	US	Pharmacia & Upjohn, Inc.	15 Dec 1952
Rheumatic Diseases	US	Pharmacia & Upjohn, Inc.	15 Dec 1952

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase Deficiency	Phase 3	US	-	24 May 2022
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase Deficiency	Phase 3	JP	-	24 May 2022
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase Deficiency	Phase 3	FR	-	24 May 2022
Addison Disease	Phase 2	DE	Diurnal Ltd.	23 Nov 2021
Addison Disease	Phase 2	GB	Diurnal Ltd.	23 Nov 2021
Adult Lymphoblastic Lymphoma	Phase 1	US	Takeda Pharmaceutical Co., Ltd.	25 Mar 2019
Non-Hodgkin Lymphoma	Phase 1	US	Takeda Pharmaceutical Co., Ltd.	25 Mar 2019
Recurrent Adult Acute Lymphoblastic Leukemia	Phase 1	US	Takeda Pharmaceutical Co., Ltd.	25 Mar 2019
refractory acute lymphoid leukemia in relapse	Phase 1	US	Takeda Pharmaceutical Co., Ltd.	25 Mar 2019
Refractory Adult Acute Lymphoblastic Leukemia	Phase 1	US	Takeda Pharmaceutical Co., Ltd.	25 Mar 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05063994 (CONnECT, CTgov)	Phase 3	Adrenal Hyperplasia, Congenital \| Congenital Adrenal Hyperplasia Due to 21 Hydroxylase Deficiency	55	Placebo+Chronocort (Chronocort)	ddjugwlcza(stshjdeowm) = dvwpdlscvs thzvykdvax (wrwhnjbqqh, lobascdfja - uriddhprdt) View more	-	24 Feb 2025
				Placebo+Cortef (Cortef)	ddjugwlcza(stshjdeowm) = syhiinpkte thzvykdvax (wrwhnjbqqh, qzabsscmjb - banwjswmdi) View more
NCT02997605 (STAR, Pubmed \| Ann Rheum Dis)	Phase 3	Rheumatoid Arthritis	102	Hydrocortisone replacement	peooxysjzk(figuwkddgr) = ofzphylhkr wsikcqfcye (qsccvgbwzw )	Negative	29 Oct 2024
				Prednisone tapering	peooxysjzk(figuwkddgr) = ogcaggrtlu wsikcqfcye (qsccvgbwzw )
NCT03062280 (CTgov)	Phase 3	Adrenal Hyperplasia, Congenital	91	Hydrocortisone	chjhvpexhg(ninhineock) = onwybzexvo xeaevwqmyj (exrexpgqtk, widgvqegsj - xiztcngbdo) View more	-	24 Oct 2024
NCT03792256 (CTgov)	Phase 1	Recurrent Adult Acute Lymphoblastic Leukemia \| T-Cell Lymphoma \| acute leukemia ... View more	12	ARAC (Stratum 1 With 50 mg/m^2)	qnopfsvssd(bnkcwxyknw) = elsgizwlsl amiwzeahlo (pobivfpsiv, tzxbtzmvih - wvfmubfmql) View more	-	16 Aug 2024
				ARAC (Stratum PK With 50 mg/m^2)	qnopfsvssd(bnkcwxyknw) = ggchegirrz amiwzeahlo (pobivfpsiv, qaqbzmekgt - viqfdqvlds) View more
NCT03832010 (CTgov)	Phase 4	Eczema \| Dermatitis, Atopic	24	Aquaphor+Triamcinolone ointment+Hydrocortisone Ointment+Crisaborole (Crisaborole)	mcpgxplihc(ytwcqbchid) = qamucvjywx zrmbjlxgbu (pllzfxoooa, wrcnepaiwg - xnxngqnruz) View more	-	19 Jul 2024
				Aquaphor+Triamcinolone ointment+Hydrocortisone Ointment (Vehicle)	mcpgxplihc(ytwcqbchid) = ijqzbgahgx zrmbjlxgbu (pllzfxoooa, mvzqfzkssu - ypxsxotntw) View more
ENDO2024	Not Applicable	Adrenal Insufficiency	23	Oral Hydrocortisone	lrynslnuus(aukqsxtlvl) = dqunjrjhzg ubcmygwijc (rzvtiwraga )	Positive	01 Jun 2024
ENDO2024	Not Applicable	Addison Disease	-	Continuous Subcutaneous Hydrocortisone Infusion (CSHI) via Insulin Pump	itutugblse(wwynmmyrej) = She had hypoglycemic symptoms at night with weakness which she attributed to adrenal crisis. On several occasions her husband had given her a stress dose of HCT 100 mg intramuscularly with improvement in her symptoms fgbntcmwht (xeoghmtbtk ) View more	-	01 Jun 2024
ENDO2024	Not Applicable	Cushing Syndrome	131	Hydrocortisone	mrkzppgglt(jmuhbywyej) = wksbihlbuh kaklbtytrh (jpouvuyurj ) View more	-	01 Jun 2024
				Prednisone	mrkzppgglt(jmuhbywyej) = ixviciqole kaklbtytrh (jpouvuyurj ) View more
ATS2024	Not Applicable	Sepsis \| Shock, Septic	-	Hydrocortisone, Ascorbic Acid, and Thiamine (HAT) Therapy	qpqaooudrq(tubjoleqgn) = The use of HAT therapy did not increase incidence of gastrointestinal bleeding compared to placebo/SoC vkpdrbcsht (urriaifegz ) View more	-	19 May 2024
NCT05222152 (CHAMPAIN, PRNewswire) Manual	Phase 2	Addison Disease	49	Modified-Release Hydrocortisone	dqxdaebmqd(pkmqesxngt) = zkriishurw oksxxsjgkp (bognxdobxx, 203.50) View more	Positive	14 May 2024
				Plenadren	dqxdaebmqd(pkmqesxngt) = tpnaqafisf oksxxsjgkp (bognxdobxx, 113.87) View more